CG Oncology
Attacking Bladder Cancer for a Better Tomorrow
121 employees · est. 2010 · Irvine, United States
Vyriad
Vyriad is a clinical-stage biotech company developing targeted genetic therapies that deliver genes directly to cells.
51 employees · est. 2015 · Rochester, United States
CG Oncology is the older company (2010 vs 2015).
Side-by-Side Comparison
| Metric | CG Oncology | Vyriad |
|---|---|---|
| Founded | ||
| Founded | 2010 older | 2015 |
| Headquarters | ||
| Headquarters | Irvine, United States | Rochester, United States |
| Employees | ||
| Employees | 121 | 51 |
| Industry | ||
| Industry | Biotechnology, Health Care | Biotechnology |
| Funding Stage | ||
| Funding Stage | Series F | Series B |
| Total Funding | ||
| Total Funding | $317.57M | $88.38M |
| Funding Rounds | ||
| Funding Rounds | 7 | 5 |
| Services | ||
| Services | Not tracked yet | Development of Viral Platforms, Manufacturing of Genetic Therapies, Preclinical and Clinical Trial Management, Collaborative Research and Development |
| Target Customers | ||
| Target Customers | Not tracked yet | Medical Institutions, Pharmaceutical Companies, Research Organizations, Healthcare Organizations |
| Taxonomy | ||
| Taxonomy | Oncolytic Immunotherapy, Bladder Cancer, Clinical-Stage Biopharmaceutical, CG0070, Immunotherapies, BioSante Pharmaceuticals, NMIBC, Phase 3 Trial, Keytruda, Opdivo, Urologic Cancer, Clinical Trial, Biopharmaceutical Company, Immunotherapy Agent, Patient Therapies | Biotech, Genetic Therapies, Oncolytic Virotherapy, Viral Vectors, Gene Editing, Cancer Treatment, Phase 1-2 Clinical Studies, Targeted Cell Therapy, Immuno-Oncology, Clinical Research Collaboration, Proprietary Oncolytic Virus, Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Squamous Cell Carcinoma |
| Website | ||
| Website | cgoncology.com | vyriad.com |
About CG Oncology
CG Oncology is a late-stage clinical biopharmaceutical company, founded in 2010, focusing on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is in a Phase 3 trial for the t...
About Vyriad
Vyriad, a United States-based clinical-stage biotech company, is making strides in the biotechnology sector by pioneering targeted genetic therapies. These therapies are designed to deliver genes directly to cells using engineered viruses, viral vectors, and envelope glycoproteins. The company's tec...
We will tell you when either one moves
BounceWatch watches CG Oncology and Vyriad for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at CG Oncology and Vyriad — by email.
Frequently Asked Questions
Compare CG Oncology with someone else
Start typing a company name or domain.
Related Comparisons
Compiled from the BounceWatch company index. We last looked at CG Oncology on 11 Sep 2024, and Vyriad on 11 Mar 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.